NASDAQ:EYPT EyePoint Pharmaceuticals (EYPT) Stock Price, News & Analysis → Trump’s Former Wingman Bets Big on AI (From Banyan Hill Publishing) (Ad) Free EYPT Stock Alerts $13.00 +0.55 (+4.42%) (As of 02:39 PM ET) Add Compare Share Share Today's Range$12.68▼$13.4250-Day Range$11.20▼$25.7452-Week Range$5.67▼$30.99Volume661,556 shsAverage Volume1.13 million shsMarket Capitalization$677.04 millionP/E RatioN/ADividend YieldN/APrice Target$33.71 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get EyePoint Pharmaceuticals alerts: Email Address EyePoint Pharmaceuticals MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside159.7% Upside$33.71 Price TargetShort InterestBearish12.67% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.37Based on 33 Articles This WeekInsider TradingAcquiring Shares$20.57 M Bought Last QuarterProj. Earnings GrowthDecreasingFrom ($2.05) to ($2.86) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.3.28 out of 5 starsMedical Sector326th out of 928 stocksAnalytical Instruments Industry11th out of 29 stocks 4.5 Analyst's Opinion Consensus RatingEyePoint Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 7 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageEyePoint Pharmaceuticals has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about EyePoint Pharmaceuticals' stock forecast and price target. Previous Next 1.0 Short Interest Percentage of Shares Shorted12.67% of the outstanding shares of EyePoint Pharmaceuticals have been sold short.Short Interest Ratio / Days to CoverEyePoint Pharmaceuticals has a short interest ratio ("days to cover") of 5.6.Change versus previous monthShort interest in EyePoint Pharmaceuticals has recently increased by 0.92%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldEyePoint Pharmaceuticals does not currently pay a dividend.Dividend GrowthEyePoint Pharmaceuticals does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for EYPT. Previous Next 3.0 News and Social Media Coverage News SentimentEyePoint Pharmaceuticals has a news sentiment score of 0.37. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.56 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 33 news articles for EyePoint Pharmaceuticals this week, compared to 4 articles on an average week.Search Interest11 people have searched for EYPT on MarketBeat in the last 30 days. This is an increase of 10% compared to the previous 30 days.MarketBeat Follows10 people have added EyePoint Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days. Previous Next 4.2 Company Ownership Insider Buying vs. Insider SellingIn the past three months, EyePoint Pharmaceuticals insiders have bought more of their company's stock than they have sold. Specifically, they have bought $20,570,223.00 in company stock and sold $0.00 in company stock.Percentage Held by Insiders13.05% of the stock of EyePoint Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions99.41% of the stock of EyePoint Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about EyePoint Pharmaceuticals' insider trading history. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for EyePoint Pharmaceuticals are expected to decrease in the coming year, from ($2.05) to ($2.86) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of EyePoint Pharmaceuticals is -7.13, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of EyePoint Pharmaceuticals is -7.13, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioEyePoint Pharmaceuticals has a P/B Ratio of 2.70. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about EyePoint Pharmaceuticals' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Allegiance GoldDoes this make you sick?The US Dollar Is "Finished" A deteriorating economy, global instability, and a weakened banking system have pushed the U.S. financial system to the brink, imperiling the value of your savings and investments.Get your Free Wealth Protection Kit About EyePoint Pharmaceuticals Stock (NASDAQ:EYPT)EyePoint Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases. The company's pipeline leverages its proprietary bioerodible Durasert E technology for sustained intraocular drug delivery. Its lead product candidate is EYP-1901, an investigational sustained delivery treatment for VEGF-mediated retinal diseases combining vorolanib, a selective and patent-protected tyrosine kinase inhibitor with Durasert E which is in Phase 2 clinical trials for wet age-related macular degeneration (wet AMD), non-proliferative diabetic retinopathy (NPDR), and diabetic macular edema (DME). The company's pipeline programs also include EYP-2301, a promising TIE-2 agonist formulated in Durasert E to potentially improve outcomes in serious retinal diseases. The company was formerly known as pSivida Corp. and changed its name to EyePoint Pharmaceuticals, Inc. in March 2018. EyePoint Pharmaceuticals, Inc. was incorporated in 1987 and is headquartered in Watertown, Massachusetts.Read More EYPT Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart EYPT Stock News HeadlinesMay 9, 2024 | insidertrades.comInsider Buying: EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Major Shareholder Acquires $10,081,000.00 in StockApril 23, 2024 | insidertrades.comInsider Buying: EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Major Shareholder Buys 581,765 Shares of StockMay 15 at 5:58 AM | americanbankingnews.comBrokers Issue Forecasts for EyePoint Pharmaceuticals, Inc.'s Q1 2025 Earnings (NASDAQ:EYPT)May 15 at 3:38 AM | americanbankingnews.comHC Wainwright Cuts EyePoint Pharmaceuticals (NASDAQ:EYPT) Price Target to $30.00May 13 at 5:08 PM | markets.businessinsider.comEyePoint Pharmaceuticals: Maintaining Buy Rating Amidst Progress and TrialsMay 13 at 2:39 AM | americanbankingnews.comCapital One Financial Weighs in on EyePoint Pharmaceuticals, Inc.'s Q2 2024 Earnings (NASDAQ:EYPT)May 12 at 5:22 AM | americanbankingnews.comEyePoint Pharmaceuticals (NASDAQ:EYPT) Given New $38.00 Price Target at Robert W. BairdMay 12 at 3:50 AM | americanbankingnews.comChardan Capital Comments on EyePoint Pharmaceuticals, Inc.'s FY2025 Earnings (NASDAQ:EYPT)May 11, 2024 | americanbankingnews.comEyePoint Pharmaceuticals (NASDAQ:EYPT) Rating Lowered to Sell at StockNews.comMay 10, 2024 | finance.yahoo.comEyePoint Pharmaceuticals Q1 2024 Earnings: Revenue Surpasses Estimates Despite ChallengesMay 10, 2024 | americanbankingnews.comCormorant Asset Management, Lp Buys 850,000 Shares of EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) StockMay 10, 2024 | americanbankingnews.comEyePoint Pharmaceuticals (NASDAQ:EYPT) Shares Gap Up on Insider Buying ActivityMay 9, 2024 | americanbankingnews.comEyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) to Post Q1 2024 Earnings of ($0.32) Per Share, Capital One Financial ForecastsMay 8, 2024 | investorplace.comEYPT Stock Earnings: EyePoint Pharmaceuticals Misses EPS, Beats Revenue for Q1 2024May 8, 2024 | globenewswire.comEyePoint Pharmaceuticals Reports First Quarter 2024 Financial Results and Highlights Recent Corporate DevelopmentsMay 8, 2024 | americanbankingnews.comEyePoint Pharmaceuticals (NASDAQ:EYPT) Price Target Cut to $30.00 by Analysts at MizuhoMay 8, 2024 | americanbankingnews.comEyePoint Pharmaceuticals (NASDAQ:EYPT) Price Target Cut to $28.00 by Analysts at Chardan CapitalMay 7, 2024 | markets.businessinsider.comMaintaining Buy Rating on EyePoint Pharmaceuticals Despite P2 Study SetbackMay 7, 2024 | seekingalpha.comEyePoint Stock: NPDR Endpoint Miss Is A Buying Opportunity Based On Lead ProgramMay 7, 2024 | markets.businessinsider.comMaintaining Buy Rating on EyePoint Pharmaceuticals: Strong Prospects in wAMD Market Despite NPDR Study SetbackMay 7, 2024 | americanbankingnews.comEyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Given Average Rating of "Buy" by AnalystsMay 6, 2024 | msn.comEyePoint tumbles 30% premarket on failed Phase 2 studyMay 6, 2024 | seekingalpha.comEyePoint's Setback In NPDR Does Not Bode Well For DME (Rating Downgrade)May 6, 2024 | finance.yahoo.comWhy Is EyePoint Pharmaceuticals Stock Plummeting On Monday?May 6, 2024 | globenewswire.comEyePoint Pharmaceuticals Announces Topline Data from the Phase 2 PAVIA Trial of DURAVYU™ in Non-Proliferative Diabetic RetinopathySee More Headlines Receive EYPT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for EyePoint Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/07/2024Today5/15/2024Next Earnings (Estimated)8/07/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Analytical instruments Sub-IndustryN/A Current SymbolNASDAQ:EYPT CUSIPN/A CIK1314102 Webeyepointpharma.com Phone(617) 926-5000Fax617-926-5050Employees121Year Founded1987Price Target and Rating Average Stock Price Target$33.71 High Stock Price Target$44.00 Low Stock Price Target$28.00 Potential Upside/Downside+152.0%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage7 Analysts Profitability EPS (Most Recent Fiscal Year)($1.82) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-70,790,000.00 Net Margins-157.77% Pretax Margin-157.60% Return on Equity-49.94% Return on Assets-30.94% Debt Debt-to-Equity RatioN/A Current Ratio5.08 Quick Ratio5.01 Sales & Book Value Annual Sales$46.02 million Price / Sales15.14 Cash FlowN/A Price / Cash FlowN/A Book Value$4.80 per share Price / Book2.79Miscellaneous Outstanding Shares52,080,000Free Float45,287,000Market Cap$696.83 million OptionableOptionable Beta1.70 Social Links The 10 Best AI Stocks to Own in 2024Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free Report Key ExecutivesDr. Jay S. Duker M.D. (Age 65)President, CEO & Director Comp: $848.5kDr. John B. Landis M.S. (Age 71)Ph.D., Interim Head of R&D and Director Comp: $63.75kMr. Michael Pine (Age 47)Chief Business Officer Comp: $764.85kMr. George O. Elston (Age 59)Executive VP & CFO Comp: $743.86kMr. Michael J. MaciocioSenior Vice President of Manufacturing & OperationsMr. Ron I. Honig Esq.Chief Legal Officer & Company SecretaryMs. Jennifer LeonardChief People Officer & Senior VP of ITMr. David Scott Jones (Age 56)Senior VP & Chief Commercial Officer Comp: $672.08kMs. Isabelle LefebvreChief Regulatory OfficerDr. Marcia Sellos-Moura Ph.D.Senior Vice President of Program LeadershipMore ExecutivesKey CompetitorsQuanterixNASDAQ:QTRXPacific Biosciences of CaliforniaNASDAQ:PACBStandard BioToolsNASDAQ:LABCytek BiosciencesNASDAQ:CTKBNautilus BiotechnologyNASDAQ:NAUTView All CompetitorsInsiders & InstitutionsPrice T Rowe Associates Inc. MDSold 56,889 shares on 5/15/2024Ownership: 4.735%Affinity Asset Advisors LLCSold 320,100 shares on 5/15/2024Ownership: 0.000%American International Group Inc.Bought 5,101 shares on 5/14/2024Ownership: 0.035%Ameritas Investment Partners Inc.Bought 1,136 shares on 5/13/2024Ownership: 0.007%Vanguard Group Inc.Bought 362,168 shares on 5/10/2024Ownership: 4.601%View All Insider TransactionsView All Institutional Transactions EYPT Stock Analysis - Frequently Asked Questions Should I buy or sell EyePoint Pharmaceuticals stock right now? 7 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for EyePoint Pharmaceuticals in the last year. There are currently 7 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" EYPT shares. View EYPT analyst ratings or view top-rated stocks. What is EyePoint Pharmaceuticals' stock price target for 2024? 7 brokers have issued 12 month target prices for EyePoint Pharmaceuticals' shares. Their EYPT share price targets range from $28.00 to $44.00. On average, they predict the company's share price to reach $33.71 in the next twelve months. This suggests a possible upside of 159.7% from the stock's current price. View analysts price targets for EYPT or view top-rated stocks among Wall Street analysts. How have EYPT shares performed in 2024? EyePoint Pharmaceuticals' stock was trading at $23.11 at the beginning of the year. Since then, EYPT stock has decreased by 43.8% and is now trading at $12.98. View the best growth stocks for 2024 here. When is EyePoint Pharmaceuticals' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, August 7th 2024. View our EYPT earnings forecast. How were EyePoint Pharmaceuticals' earnings last quarter? EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) issued its quarterly earnings data on Thursday, March, 7th. The company reported ($0.33) earnings per share for the quarter, beating analysts' consensus estimates of ($0.60) by $0.27. The company earned $14.03 million during the quarter, compared to analysts' expectations of $8.71 million. EyePoint Pharmaceuticals had a negative trailing twelve-month return on equity of 49.94% and a negative net margin of 157.77%. During the same period last year, the business posted ($0.61) EPS. What ETFs hold EyePoint Pharmaceuticals' stock? ETFs with the largest weight of EyePoint Pharmaceuticals (NASDAQ:EYPT) stock in their portfolio include SPDR S&P Pharmaceuticals ETF (XPH) and Direxion Daily Pharmaceutical & Medical Bull 3X Shares (PILL).Invesco Biotechnology & Genome ETF (PBE). When did EyePoint Pharmaceuticals' stock split? Shares of EyePoint Pharmaceuticals reverse split on the morning of Wednesday, December 9th 2020. The 1-10 reverse split was announced on Tuesday, December 8th 2020. The number of shares owned by shareholders was adjusted after the market closes on Wednesday, December 9th 2020. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split. What other stocks do shareholders of EyePoint Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other EyePoint Pharmaceuticals investors own include Sorrento Therapeutics (SRNE), OPKO Health (OPK), Inovio Pharmaceuticals (INO), Verastem (VSTM), XOMA (XOMA), AcelRx Pharmaceuticals (ACRX), Catalyst Pharmaceuticals (CPRX), Progenics Pharmaceuticals (PGNX), Corbus Pharmaceuticals (CRBP) and Dynavax Technologies (DVAX). Who are EyePoint Pharmaceuticals' major shareholders? EyePoint Pharmaceuticals' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Price T Rowe Associates Inc. MD (4.73%), Vanguard Group Inc. (4.60%), Lord Abbett & CO. LLC (0.47%), Essex Investment Management Co. LLC (0.29%), Swiss National Bank (0.17%) and Legacy Capital Group California Inc. (0.06%). Insiders that own company stock include Cormorant Asset Management, Lp, Dario A Paggiarino, David Scott Jones, Ew Healthcare Partners, LP, Michael Craig Pine and Ye Liu. View institutional ownership trends. How do I buy shares of EyePoint Pharmaceuticals? Shares of EYPT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:EYPT) was last updated on 5/15/2024 by MarketBeat.com Staff From Our PartnersBill Clinton Backing Biden Replacement???The Freeport SocietyDoes this make you sick?Allegiance Goldis this a buy and hold stock?Tips4TradersTech GIANT’s Plans to Revolutionize Crypto…Crypto 101 MediaThe 2024 Gold Rush: Unleashing Market PotentialPriority GoldTrump Reveals Conspiracy Behind Fed-Controlled Digital Currency.Monetary GoldForget the “Magnificent 7” Tech Companies, Buy This AI Stock InsteadBanyan Hill PublishingTop 5 Tech Stocks to Buy for 2024Daily Market Alerts Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding EyePoint Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
